Sandalova, S., Dal, U., & Sandalov, A. (2026). Early Post-Marketing Safety Signals of Anifrolumab in EudraVigilance: A Belimumab-Comparator Disproportionality Analysis. International Journal of Medical Students. Retrieved from https://ijms.info/IJMS/article/view/4785